CRISPR-edited wheat significantly lowers free asparagine in grain—up to 59% in single edits and even 93% in a dual-gene knockout line—without sacrificing yield, compared with conventional varieties and traditional TILLING methods.

The Rothamsted Research team used CRISPR to reduce free asparagine, a precursor to acrylamide that forms during baking and toasting, highlighting a potential health benefit.

A second, partially silenced gene line achieved an even greater reduction in asparagine, illustrating precision editing advantages over mutagenesis, which lowers asparagine but can reduce yields.

EU regulatory considerations and ongoing SPS rule negotiations could affect adoption in the UK, especially if alignment with EU food rules occurs without a carve-out.

Rothamsted’s news release notes the regulatory landscape and possible health benefits as the project progresses, with ongoing discussions among researchers.

Current trials are experimental, with collaborations across Karlsruhe Institute of Technology, Leibniz Institute for Food Systems Biology, and Technical University of Munich exploring large-scale field tests and engaging millers and bakers.

Industry relevance is high since lower acrylamide could help manufacturers meet safety standards without altering recipes or production lines, potentially improving consumer safety and preserving quality.

Finished products showed lab-confirmed reductions, with some bread and cookies remaining below acrylamide detection after toasting, aligning with EU plans to set binding limits later this year.

If regulatory hurdles are cleared, this wheat could be among Europe’s first gene-edited cereals, signaling a shift toward health-focused traits in plant breeding.

EU restrictions on high-acrylamide products could affect exports from the UK, while low-acrylamide wheat would help meet safety standards and reduce consumer exposure.

Lead researcher Dr. Navneet Kaur emphasizes CRISPR’s precise, beneficial crop changes and notes that supportive regulatory frameworks can unlock major benefits for agriculture and food systems.

Regulatory context remains contentious, with the UK and EU approving pathways differing for edited crops; proponents argue clear health benefits and the absence of foreign DNA may aid acceptance.